INVESTOR RELATIONS COMPANY PLATFORMS CLINICAL STUDIES CAREERS PUBLICATIONS NEWS CONTACT We boldly develop novel therapeutics utilizing mRNA-based cell engineering and complex cytokines. Our Focus Brooklyn ImmunoTherapeutics (BTX) is committed to creating a world in which patients and families with high unmet medical needs have access to effective treatments. To achieve this, we are focused on three primary approaches: iPSC-derived, iMSC therapeutics In vivo gene editing therapeutics Complex human-derived mixed cytokines Latest News November 29, 2021 Brooklyn ImmunoTherapeutics Welcomes Susan McClatchey as Vice President and Head of Quality October 14, 2021 Brooklyn ImmunoTherapeutics to Move Stock Exchange Listing to Nasdaq September 22, 2021 Brooklyn ImmunoTherapeutics Appoints Roger Sidhu, M.D. as Chief Medical Officer READ MORE Privacy Policy Terms of Use © 2021 Brooklyn ImmunoTherapeutics

INVESTOR RELATIONS COMPANY PLATFORMS CLINICAL STUDIES CAREERS PUBLICATIONS NEWS CONTACT Do you have questions? Contact us. We'll respond promptly. Contact Us SEND Brooklyn Facility & Mailing Address Brooklyn Army Terminal 140 58th Street Suite 2100 Brooklyn, NY 11220 Please email vendor invoices to: ap@brooklynitx.com Cambridge Facility 1035 Cambridge Street, Suite 17B Cambridge, MA 02141 Privacy Policy Terms of Use © 2021 Brooklyn ImmunoTherapeutics